Do analysts rate INAB or HCWB?

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 2,280.95%. Given HCW Biologics' higher probable upside, analysts clearly believe HCW Biologics is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INAB or HCWB more profitable?

IN8bio has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. IN8bio's return on equity of -91.18% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% HCW Biologics -83.03% -262.33% -34.90%

Do analysts recommend HCWB or SYBX?

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, HCWB or SYBX?

HCW Biologics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HCW Biologics $50K 56.45 -$7.96M -$27.60 N/A Synlogic $8K 1,622.99 -$23.36M -$0.06 N/A

Is HCWB or SYBX more profitable?

Synlogic has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Synlogic's return on equity of -26.47% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -83.03% -262.33% -34.90% Synlogic N/A -26.47% -18.00%

Does the media favor HCWB or SYBX?

In the previous week, HCW Biologics had 4 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for HCW Biologics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.75 beat HCW Biologics' score of 0.49 indicating that Synlogic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Synlogic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HCWB or ALVR?

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HCWB or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. AlloVir's return on equity of -71.03% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -83.03% -262.33% -34.90% AlloVir N/A -71.03% -61.27%

Do analysts recommend HCWB or TPST?

HCW Biologics presently has a consensus price target of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to HCWB or TPST?

In the previous week, HCW Biologics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for HCW Biologics and 3 mentions for Tempest Therapeutics. HCW Biologics' average media sentiment score of 0.49 beat Tempest Therapeutics' score of 0.26 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HCWB or GTBP?

HCW Biologics currently has a consensus target price of $30.00, indicating a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HCWB or GTBP more profitable?

GT Biopharma has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. GT Biopharma's return on equity of -213.16% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -83.03% -262.33% -34.90% GT Biopharma N/A -213.16% -150.61%

HCW Biologics (HCWB) Competitors

$1.16 -0.10 (-7.94%)

As of 03:46 PM Eastern

Compare

HCWB vs. INAB, SYBX, ALVR, TPST, and GTBP

Should you buy HCW Biologics stock or one of its competitors? HCW Biologics's main competitors and comparable companies include IN8bio (INAB), Synlogic (SYBX), AlloVir (ALVR), Tempest Therapeutics (TPST), and GT Biopharma (GTBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does HCW Biologics compare to IN8bio?

IN8bio (NASDAQ:INAB) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

IN8bio has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. IN8bio's return on equity of -91.18% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
HCW Biologics	-83.03%	-262.33%	-34.90%

IN8bio has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market.

HCW Biologics has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
HCW Biologics	$50K	56.45	-$7.96M	-$27.60	N/A

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 2,280.95%. Given HCW Biologics' higher probable upside, analysts clearly believe HCW Biologics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

92.1% of IN8bio shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, HCW Biologics had 4 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for HCW Biologics and 1 mentions for IN8bio. IN8bio's average media sentiment score of 0.91 beat HCW Biologics' score of 0.49 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
HCW Biologics	Neutral

Summary

HCW Biologics beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to Synlogic?

HCW Biologics (NASDAQ:HCWB) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Synlogic has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Synlogic's return on equity of -26.47% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Synlogic	N/A	-26.47%	-18.00%

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synlogic	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HCW Biologics has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, HCW Biologics had 4 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for HCW Biologics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 0.75 beat HCW Biologics' score of 0.49 indicating that Synlogic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synlogic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HCW Biologics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	56.45	-$7.96M	-$27.60	N/A
Synlogic	$8K	1,622.99	-$23.36M	-$0.06	N/A

Summary

HCW Biologics beats Synlogic on 9 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to AlloVir?

HCW Biologics (NASDAQ:HCWB) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, HCW Biologics had 5 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for HCW Biologics and 0 mentions for AlloVir. HCW Biologics' average media sentiment score of 0.49 beat AlloVir's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Neutral
AlloVir	Neutral

HCW Biologics has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

HCW Biologics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	56.45	-$7.96M	-$27.60	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

AlloVir has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. AlloVir's return on equity of -71.03% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
AlloVir	N/A	-71.03%	-61.27%

Summary

HCW Biologics beats AlloVir on 10 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to Tempest Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, HCW Biologics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for HCW Biologics and 3 mentions for Tempest Therapeutics. HCW Biologics' average media sentiment score of 0.49 beat Tempest Therapeutics' score of 0.26 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HCW Biologics has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	56.45	-$7.96M	-$27.60	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

HCW Biologics presently has a consensus price target of $30.00, suggesting a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HCW Biologics has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, indicating that its share price is 273% less volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. HCW Biologics' return on equity of -262.33% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Tempest Therapeutics	N/A	-576.56%	-134.99%

Summary

HCW Biologics beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to GT Biopharma?

HCW Biologics (NASDAQ:HCWB) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

GT Biopharma has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. GT Biopharma's return on equity of -213.16% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
GT Biopharma	N/A	-213.16%	-150.61%

HCW Biologics has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, HCW Biologics had 4 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for HCW Biologics and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.87 beat HCW Biologics' score of 0.49 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
HCW Biologics	Neutral
GT Biopharma	Very Positive

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HCW Biologics currently has a consensus target price of $30.00, indicating a potential upside of 2,280.95%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HCW Biologics has higher revenue and earnings than GT Biopharma. HCW Biologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	56.45	-$7.96M	-$27.60	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

Summary

HCW Biologics beats GT Biopharma on 10 of the 14 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60M	$3.90B	$7.29B	$12.91B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.04	12.96	275.68	25.25
Price / Sales	51.97	1,151.37	562.78	78.51
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.23	16.59	10.54	5.92
Net Income	-$7.96M	-$22.69M	$3.50B	$381.16M
7 Day Performance	-25.64%	-6.38%	-4.13%	-4.32%
1 Month Performance	-47.27%	-14.15%	-8.51%	-7.19%
1 Year Performance	-95.70%	6.41%	2.12%	-4.99%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	3.2524 of 5 stars	$1.16 -7.9%	$30.00 +2,486.2%	-95.0%	$2.60M	$50K	N/A	35
INAB IN8bio	1.9286 of 5 stars	$1.40 +0.7%	$4.00 +185.7%	-45.6%	$13.70M	N/A	N/A	18	Positive News
SYBX Synlogic	N/A	$1.10 +2.8%	N/A	-31.6%	$13.47M	$8K	N/A	80	News Coverage Gap Up
ALVR AlloVir	N/A	$2.66 -6.0%	N/A	-49.2%	$13.41M	N/A	N/A	110	High Trading Volume
TPST Tempest Therapeutics	0.6983 of 5 stars	$0.79 +0.5%	N/A	-94.1%	$13.30M	N/A	N/A	4	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. INAB, SYBX, ALVR, TPST, and GTBP

How does HCW Biologics compare to IN8bio?

Summary

How does HCW Biologics compare to Synlogic?

Summary

How does HCW Biologics compare to AlloVir?

Summary

How does HCW Biologics compare to Tempest Therapeutics?

Summary

How does HCW Biologics compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. INAB, SYBX, ALVR, TPST, and GTBP

How does HCW Biologics compare to IN8bio?

Is INAB or HCWB more profitable?

Which has more risk and volatility, INAB or HCWB?

Which has better valuation and earnings, INAB or HCWB?

Do analysts rate INAB or HCWB?

Do institutionals and insiders have more ownership in INAB or HCWB?

Does the media refer more to INAB or HCWB?

Summary

How does HCW Biologics compare to Synlogic?

Is HCWB or SYBX more profitable?

Do analysts recommend HCWB or SYBX?

Do insiders and institutionals have more ownership in HCWB or SYBX?

Which has more volatility & risk, HCWB or SYBX?

Does the media favor HCWB or SYBX?

Which has higher earnings & valuation, HCWB or SYBX?

Summary

How does HCW Biologics compare to AlloVir?

Does the media prefer HCWB or ALVR?

Which has more volatility and risk, HCWB or ALVR?

Do institutionals and insiders hold more shares of HCWB or ALVR?

Do analysts recommend HCWB or ALVR?

Which has higher valuation and earnings, HCWB or ALVR?

Is HCWB or ALVR more profitable?

Summary

How does HCW Biologics compare to Tempest Therapeutics?

Does the media refer more to HCWB or TPST?

Which has preferable earnings & valuation, HCWB or TPST?

Do analysts recommend HCWB or TPST?

Do insiders & institutionals have more ownership in HCWB or TPST?

Which has more volatility and risk, HCWB or TPST?

Is HCWB or TPST more profitable?

Summary

How does HCW Biologics compare to GT Biopharma?

Is HCWB or GTBP more profitable?

Which has more volatility and risk, HCWB or GTBP?

Does the media refer more to HCWB or GTBP?

Do institutionals and insiders have more ownership in HCWB or GTBP?

Do analysts prefer HCWB or GTBP?

Which has preferable earnings & valuation, HCWB or GTBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools